At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 111 enrolled
Drug / intervention
MC2-25 cream +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Parallel-group (2-Arm), Randomized, Double-blind, 12-week Trial to Evaluate the Efficacy and Safety of MC2-25 Cream and MC2-25 Vehicle in Subjects With Chronic Kidney Disease-associated Pruritus (CKD-aP)
In Brief
A Phase 2 clinical trial evaluating MC2-25 cream and MC2-25 vehicle for Chronic Kidney Disease-associated Pruritus. Completed, enrolled 111 participants across 1 site.
Detailed Summary
The purpose of this study is to access the efficacy and safety of MC2-25 cream and MC2-25 vehicle for treatment of chronic kidney disease associated pruritus (CKD)-aP).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
2023202420252026
Enrollment StartJul 2022
First PostedAug 2022
Primary CompletionFeb 2024
TodayJul 2026
First PostedAug 1, 2022
Enrollment StartJul 1, 2022
Primary CompletionFeb 2, 2024
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 3.9 years ago
Interventions
MC2-25 creamdrug
Topical application
MC2-25 vehicledrug
Topical application